Lexaria Bioscience Corp.
NASDAQ Capital MarketTotal Valuation
Lexaria Bioscience Corp. carries a market capitalization of 29,687.00, placing it among publicly traded companies globally. Its enterprise value stands at -5.57M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 29,687.00 |
| Enterprise Value | -5.57M |
Share Statistics
Lexaria Bioscience Corp. currently has 24.89M shares outstanding.
| Shares Outstanding | 24.89M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Lexaria Bioscience Corp. maintains a current ratio of 26.88, meaning it holds 26.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 26.88 |
| Quick Ratio | 24.74 |
| Debt / Equity | 1.52 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -117.07 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 4,389.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Lexaria Bioscience Corp.'s stock has declined approximately -99.5% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.16.
| Beta (5Y) | N/A |
| 52-Week Price Change | -99.5% |
| 50-Day Moving Average | 0.03 |
| 200-Day Moving Average | 0.16 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -9.38M, while operating income came in at -9.46M.
| Revenue | 368,000.00 |
| Gross Profit | 368,000.00 |
| Operating Income | -9.46M |
| Pretax Income | -9.53M |
| Net Income | -9.53M |
| EBITDA | -9.38M |
| EBIT | -9.46M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Lexaria Bioscience Corp. holds 5.27M in cash and equivalents against 94,386.00 in total debt, resulting in a net debt position of -5.13M. Total book value stands at -66.48M, with working capital of 5.56M providing operational flexibility.
| Cash & Cash Equivalents | 5.27M |
| Total Debt | 94,386.00 |
| Net Debt | -5.13M |
| Equity (Book Value) | -66.48M |
| Book Value Per Share | N/A |
| Working Capital | 5.56M |
Cash Flow
Lexaria Bioscience Corp. produced -9.37M in operating cash flow over the past twelve months.
| Operating Cash Flow | -9.37M |
| Capital Expenditures | -95,063.00 |
| Free Cash Flow | -9.47M |
| FCF Per Share | N/A |
Margins
Lexaria Bioscience Corp. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -2,571.89 and net profit margin of -2,589.65 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -2,571.89 |
| Pretax Margin | -2,590.67 |
| Profit Margin | -2,589.65 |
| EBITDA Margin | -2,547.89 |
Scores
Lexaria Bioscience Corp. posts an Altman Z-Score of -19.01, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -19.01 |